How GlaxoSmithKline plc’s first-mover advantage could power future profits

GlaxoSmithkline plc (LON: GSK) could be looking at its next blockbuster.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, eighteen months earlier than planned, GlaxoSmithKline (LSE: GSK) announced the filing of a regulatory submission with the US Food and Drug Administration for the firm’s new three-in-one lung drug.

The company plans a regulatory filing in the EU during the coming weeks and expects to follow that with submissions in other countries. Assuming GSK get the approvals it needs for the new treatment, first-mover advantage could mean the treatment hits the market as early as 2017, beating the firm’s rival treatments, which appear to remain in development.

The potential market is huge

GSK and its research partner Innoviva are up against competitors such as AstraZeneca and Novartis to develop what they refer to as “closed triple” therapies, which aim to treat chronic obstructive pulmonary disease (COPD) with a once-daily single inhaler.

The announcement from GSK today follows a commitment earlier this year to bring forward the timing of the US filing from the first half of 2018. Now, the firm seems on course to beat its rivals to the market with the therapy, which could go on to achieve blockbuster sales for GSK.

The potential market is huge, with COPD affecting around 329 m people worldwide. It is a disease of the lungs that includes chronic bronchitis and emphysema, brought on by long-term exposure to lung irritants such as cigarette smoke, breathing in second-hand smoke, air pollution, chemical fumes or dust from the environment or workplace.

GSK is up against falling sales of older respiratory treatments such as dual therapy inhaler Advair and sees the new triple as a big opportunity. According to Reuters, outgoing chief executive Andrew Witty said the new treatment could be an “absolute clincher” for GSK’s respiratory business.

Ballooning earnings

I reckon the emergence of GSK’s potential new triple COPD treatment is more evidence of the firm’s potential to rebuild its business from its development pipeline after the well-reported patent-cliff headaches of recent years. Treatments timing out on patents sell for less as the market becomes swamped with generic competition. When that happens, profits dive.

However, City analysts following GSK are optimistic. They see earnings ballooning by 31% this year and an uplift of 10% during 2017. After four years of declining earnings, this looks like a significant turnaround for GSK’s fortunes that underlines the value and power of the company’s vibrant research and development operation.

The combination of weighty research and development feeding a robust consumer goods market such as medicines makes GSK an attractive defensive, growing business and an ideal vehicle for investors seeking compounding returns. That’s why master investors such as Neil Woodford are so keen on the shares.

If this new COPD treatment goes on to deliver on profits as hoped, you might end up being glad you looked closely at the opportunity with GSK today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »